This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
MicroRNA profiles and initiation, diagnosis and treatment of cancers in digestive organs
Xin Li, Xiao-Qing Li, Shi-Ang Huang
Xin Li, Xiao-Qing Li, Shi-Ang Huang, Stem Cell Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology; Key Laboratory for Bio-targeted Therapy of Hubei Province, Wuhan 430022, Hubei Province, China
Supported by: the National Science Foundation for Distinguished Young Scholars, No. 30225038.
Correspondence to: Shi-Ang Huang, Stem Cell Center, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology; Key Lab for Bio-targeted Therapy of Hubei Province, Wuhan 430022, Hubei Province, China. email@example.com
Received: February 8, 2007 Revised: February 1, 2007 Accepted: February 21, 2007 Published online: April 18, 2007
MicroRNA (miRNA) is a kind of small non-coding RNA containin 21 to 23 nucleotides in length that down-regulates gene expression during various crucial cell processes such as development, proliferation, differentiation and apoptosis. Recent studies supported an important role of miRNA in the initiation and progression of human malignancies. Some miRNAs may function as oncogenes or tumor suppressors. It is found that several miRNAs are directly involved in human cancers of digestive organs, including liver, colon, stomach, pancreas and bile duct. In addition, miRNA expression profiling of tumors in digestive organs has identified signatures associated with diagnosis, staging, progression, prognosis and response to treatment. Profiling has also been exploited to identify miRNA genes that might represent downstream targets of activated oncogenic pathways, or target protein coding genes involved in cancer. Moveover, miRNA-mediated therapy may be a powerful tool for cancer prevention and therapy.
Key Words: MicroRNA; Expression profile; Tumor; Digestive organ
Citation: Li X, Li XQ, Huang SA. MicroRNA profiles and initiation, diagnosis and treatment of cancers in digestive organs. Shijie Huaren Xiaohua Zazhi 2007; 15(11): 1241-1245
Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer.Nat Rev Cancer. 2006;6:259-269.
Chen CZ. MicroRNAs as oncogenes and tumor suppressors.N Engl J Med. 2005;353:1768-1771.
Calin GA, Croce CM. MicroRNA signatures in human cancers.Nat Rev Cancer. 2006;6:857-866.
Hwang HW, Mendell JT. MicroRNAs in cell proliferation, cell death, and tumorigenesis.Br J Cancer. 2006;94:776-780.
Narayan S, Roy D. Role of APC and DNA mismatch repair genes in the development of colorectal cancers.Mol Cancer. 2003;2:41.
Bandrés E, Cubedo E, Agirre X, Malumbres R, Zárate R, Ramirez N, Abajo A, Navarro A, Moreno I, Monzó M. Identification by Real-time PCR of 13 mature microRNAs differentially expressed in colorectal cancer and non-tumoral tissues.Mol Cancer. 2006;5:29.
Akao Y, Nakagawa Y, Naoe T. let-7 microRNA functions as a potential growth suppressor in human colon cancer cells.Biol Pharm Bull. 2006;29:903-906.
Michael MZ, O' Connor SM, van Holst Pellekaan NG, Young GP, James RJ. Reduced accumulation of specific microRNAs in colorectal neoplasia.Mol Cancer Res. 2003;1:882-891.
Johnson SM, Grosshans H, Shingara J, Byrom M, Jarvis R, Cheng A, Labourier E, Reinert KL, Brown D, Slack FJ. RAS is regulated by the let-7 microRNA family.Cell. 2005;120:635-647.
Meng F, Henson R, Lang M, Wehbe H, Maheshwari S, Mendell JT, Jiang J, Schmittgen TD, Patel T. Involvement of human micro-RNA in growth and response to chemotherapy in human cholangiocarcinoma cell lines.Gastroenterology. 2006;130:2113-2129.
Lee EJ, Gusev Y, Jiang J, Nuovo GJ, Lerner MR, Frankel WL, Morgan DL, Postier RG, Brackett DJ, Schmittgen TD. Expression profiling identifies microRNA signature in pancreatic cancer.Int J Cancer. 2007;120:1046-1054.
Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M. A microRNA expression signature of human solid tumors defines cancer gene targets.Proc Natl Acad Sci U S A. 2006;103:2257-2261.
Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA. MicroRNA expression profiles classify human cancers.Nature. 2005;435:834-838.
Jin G, Hu XG, Ying K, Tang Y, Liu R, Zhang YJ, Jing ZP, Xie Y, Mao YM. Discovery and analysis of pancreatic adenocarcinoma genes using cDNA microarrays.World J Gastroenterol. 2005;11:6543-6548.
Wulfkuhle J, Espina V, Liotta L, Petricoin E. Genomic and proteomic technologies for individualisation and improvement of cancer treatment.Eur J Cancer. 2004;40:2623-2632.
Shachaf CM, Kopelman AM, Arvanitis C, Karlsson A, Beer S, Mandl S, Bachmann MH, Borowsky AD, Ruebner B, Cardiff RD. MYC inactivation uncovers pluripotent differentiation and tumour dormancy in hepatocellular cancer.Nature. 2004;431:1112-1117.
Murakami Y, Yasuda T, Saigo K, Urashima T, Toyoda H, Okanoue T, Shimotohno K. Comprehensive analysis of microRNA expression patterns in hepatocellular carcinoma and non-tumorous tissues.Oncogene. 2006;25:2537-2545.
Kutay H, Bai S, Datta J, Motiwala T, Pogribny I, Frankel W, Jacob ST, Ghoshal K. Downregulation of miR-122 in the rodent and human hepatocellular carcinomas.J Cell Biochem. 2006;99:671-678.
Chang J, Nicolas E, Marks D, Sander C, Lerro A, Buendia MA, Xu C, Mason WS, Moloshok T, Bort R. miR-122, a mammalian liver-specific microRNA, is processed from hcr mRNA and may downregulate the high affinity cationic amino acid transporter CAT-1.RNA Biol. 2004;1:106-113.
Jopling CL, Yi M, Lancaster AM, Lemon SM, Sarnow P. Modulation of hepatitis C virus RNA abundance by a liver-specific MicroRNA.Science. 2005;309:1577-1581.
He L, Thomson JM, Hemann MT, Hernando-Monge E, Mu D, Goodson S, Powers S, Cordon-Cardo C, Lowe SW, Hannon GJ. A microRNA polycistron as a potential human oncogene.Nature. 2005;435:828-833.
Zhang B, Pan X, Cobb GP, Anderson TA. microRNAs as oncogenes and tumor suppressors.Dev Biol. 2007;302:1-12.
Cummins JM, Velculescu VE. Implications of micro-RNA profiling for cancer diagnosis.Oncogene. 2006;25:6220-6227.
Weiler J, Hunziker J, Hall J. Anti-miRNA oligonucleotides (AMOs): ammunition to target miRNAs implicated in human disease?Gene Ther. 2006;13:496-502.
Krützfeldt J, Rajewsky N, Braich R, Rajeev KG, Tuschl T, Manoharan M, Stoffel M. Silencing of microRNAs in vivo with 'antagomirs'.Nature. 2005;438:685-689.
Hammond SM. MicroRNA therapeutics: a new niche for antisense nucleic acids.Trends Mol Med. 2006;12:99-101.
Devi GR. siRNA-based approaches in cancer therapy.Cancer Gene Ther. 2006;13:819-829.